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Abstract
The continued advance of antibiotic resistance in clinically relevant bacterial strains necessitates 
the development and refinement of assays that can rapidly and cost-effectively identify bacteria 
and determine their susceptibility to a panel of antibiotics. A methodology is described herein that 
exploits the specificity and physiology of the Staphylococci bacteriophage K to identify 
Staphylococcus aureus (S. aureus) and determine its susceptibility to clindamycin and cefoxitin. 
The method uses liquid chromatography–mass spectrometry to monitor the replication of 
bacteriophage after it is used to infect samples thought to contain S. aureus. Amplification of 
bacteriophage K indicates the sample contains S. aureus, for it is only in the presence of a suitable 
host that bacteriophage K can amplify. If bacteriophage amplification is detected in samples 
containing the antibiotics clindamycin or cefoxitin, the sample is deemed to be resistant to these 
antibiotics, respectively, for bacteriophage can only amplify in a viable host. Thus, with a single 
work flow, S. aureus can be detected in an unknown sample and susceptibility to clindamycin and 
cefoxitin can be ascertained. This Article discusses implications for the use of bacteriophage 
amplification in the clinical laboratory.
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Shortly following the introduction of antibiotics to combat Staphylococci infections, 
evidence arose showing the emergence of multiple Staphylococcus strains resistant to the 
prescribed antibiotics.1 Today, antibiotic resistance among both Gram-positive bacteria, such 
as Staphylococcus aureus,2 and Gram-negative bacteria, such as extended-spectrum beta-
lactamase Escherichia coli and Klebsiella sp,3 is endemic and problematic in nosocomial 
and community settings. Further, the economic burden of antibiotic resistant bacteria is 
substantial,4,5 and the specter of increasing numbers of resistant strains and the lack of 
adequate antibiotics to ameliorate the impact of these strains is of profound concern.6 
Implicit in the proper treatment regimen of bacterial infections is the rapid and accurate 
ascertainment of which bacteria are present and a determination of their susceptibility to 
specific antibiotics.7
Bacteriophage amplification detection (PAD) is an emerging technique for bacterial 
identification. Using PAD, the presence of a specific, viable bacterium is determined by 
detecting the replication of a selective bacteriophage that has purposely been introduced into 
the sample.8,9 The well-documented specificity of a bacteriophage for its host is exploited in 
PAD, wherein a phage can only replicate in the presence of a suitable host. By manipulating 
the concentration of the introduced bacteriophage below the detection limit of the chosen 
detector, or by marking the phage so that introduced bacteriophage can be distinguished by 
the detector from newly amplified bacteriophage, an increased concentration of 
bacteriophage in a sample can be readily monitored. Detectors that can specifically 
distinguish structural components of the bacteriophage, such as mass spectrometry or 
immuno-diagnostics, allow the implication of the presence of a bacterium in a sample 
without the need to utilize bacterial colony isolation techniques prior to analysis, a time-
consuming process.10
Though discussed in a limited fashion in the scientific literature, PAD can also be used to 
ascertain antibiotic resistance of a bacterial strain in addition to establishing identity.11,12 
The general PAD methodology to determine identification and antibiotic susceptibility of a 
bacterial strain is to split a sample in two and add bacteriophage to Fraction A while adding 
antibiotic and bacteriophage to Fraction B. Using this design, if Fraction A shows phage 
amplification, that implies the presence of the bacterium for which the phage is specific. 
Subsequently, if Fraction B shows no phage amplification, then the bacterium is susceptible 
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to the antibiotic (at that concentration), because phage amplification can only occur in viable 
strains of bacteria. If Fraction B shows amplification of phage, then the bacterial strain is 
resistant to the derived concentration of antibiotic.
The methods most widely used in clinical microbiology laboratories across the world to 
identify bacteria and determine antibiotic resistance are based upon culture, where time to 
report results ranges from 24 to 48 h for rapidly growing bacteria. Routine culture 
methodologies include isolation and subculture of a strain, incubation, assignment of 
bacterial identification, and antibiotic susceptibility testing. The recent commercial 
introduction of MALDI-MS-based instrumentation holds promise to improve time-to-results 
for bacterial identification,13,14 and several workflows have been proposed for detecting 
drug-resistant strains.15–17 PCR assays are available for rapid antibiotic resistance 
determination for MRSA/MSSA detection, but these tests are relatively expensive, and 
cannot distinguish between live and dead bacteria.18 Further, not all strains of MRSA 
contain the mecA gene at which PCR probes are targeted.19,20
For this study, we use liquid chromatography coupled with multiple reaction monitoring 
mass spectrometry (LC-MS/MRM) to monitor the progress of PAD experiments designed to 
detect S. aureus. The bacteriophage utilized in this study is Staphylococcus phage K, a well-
characterized bacteriophage with a wide virulence against S. aureus strains and a known 
genome.21 PAD experiments were conducted without antibiotic to determine identification 
of S. aureus. Additionally, PAD was implemented in the presence of cefoxitin, a commonly 
used small molecule for testing susceptibility to beta lactam antibiotics, and clindamycin, a 
protein synthesis inhibitor of the lincosamide class used to treat MRSA in skin and soft 
tissue infections.22 We report conditions necessary for successful determination of antibiotic 
susceptibility, as well as issues regarding expansion of the methodology for use in clinical 
laboratories.
MATERIALS AND METHODS
Phage Propagation
All experiments using bacteriophage and bacterial strains were conducted in a biosafety 
level 2 laboratory. We purchased bacteriophage K and its host (ATCC-19685) from the 
American Type Culture Collection (ATCC) (Manassas, VA). Bacteriophage K was 
propagated by combining 1 mL of host grown to density with 104 pfu/mL of bacteriophage 
and spreading the milieu on top of a TSB agar plate. After overnight incubation, tryptic soy 
broth (TSB) was poured on the agar plate, the surface agitated with a disposable plastic 
spreading loop, and the contents aspirated with a pipet and placed in a centrifuge tube. 
Following centrifugation to remove debris, phage preparations were filtered through a 0.2 
μm filter and refrigerated until further use. 15N phage were propagated in like manner, 
substituting 15N enriched growth media (Cambridge Isotope Laboratories, Inc., Tewksbury, 
MA) for TSB in all broths and agar plates. To ensure complete incorporation of 15N into the 
protein structure of bacteriophages, propagation bacteria were subcultured twice in 15N 
growth media prior to infection with bacteriophage. Concentrations of bacteriophage stocks 
were determined by traditional plaque assay.
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Bacteria Strains and Antibiotic Susceptibility Determination
The bacterial strains ATCC-12598 (S. aureus), ATCC-25923 (S. aureus), ATCC-29213 (S. 
aureus), ATCC-43300 (S. aureus), BAA-1707 (S. aureus), BAA-1720 (S. aureus), 
ATCC-35547 (S. epidermidis), and ATCC-1706 (Klebsiella pneumoniae) were purchased 
from the American Type Culture Collection (ATCC) (Manassas, VA). For all phage 
amplification experiments described in this paper, bacterial strains were grown overnight in 
TSB broth, with estimates of concentration determined as described by Pierce et al.9 
Clindamycin and cefoxitin salts were obtained from Sigma-Aldrich (St. Louis, MO) and 
dissolved in deionized water. Antibiotic susceptibility of bacterial strains was determined 
according to Clinical and Laboratory Standards Institute (CLSI) guidelines using guiding 
document M100-S25. Briefly, colonies of each bacterial strain were suspended in cation-
adjusted Mueller-Hinton broth equal to a 0.5 McFarland standard. To aliquots of each 
suspension were added either cefoxitin or clindamycin at concentrations of 0, 0.5, 1, 2, 4, 8, 
16, or 32 μg/mL in a 96-well plate. After incubation for 20–24 h, growth of bacteria in each 
respective well was determined. Antibiotic resistance was determined if growth was detected 
in wells with ≥4 μg/mL of cefoxitin relative to quality control strains or ≥2 μg/mL of 
clindamycin. Table 1 summarizes the bacterial strains used in this experiment and the results 
of antibiotic resistance determination.
PAD Experimentation
“Parent” phage are defined as bacteriophage that are introduced into a sample at the 
beginning of a PAD experiment to initiate the phage infection, and “progeny” phage are 
defined as all bacteriophage generated during the course of the infection by the parent 
phage. All phage amplification experiments were conducted using 15N-labeled 
bacteriophage as the parent phage to differentiate signal derived from the parent from the 
newly generated progeny phage containing 14N-labeled proteins. PAD experiments were 
carried out in TSB by inoculating bacteria grown overnight into a sample containing parent 
phage with or without cefoxitin or clindamycin. To identify S. aureus, PAD experiments 
were set up using 1 × 107 cfu/mL of bacteria and 5 × 108 pfu/mL of 15N labeled 
bacteriophage, and allowed to incubate for 5 h at 37 °C. For clindamycin-resistance 
determination, experiments were conducted using 1 × 107 cfu/mL bacteria and 5 × 108 
pfu/mL 15N labeled bacteriophage combined with 2 μg/mL clindamycin, and allowed to 
incubate for 5 h at 37 °C. For cefoxitin resistance determination, 1 × 107 cfu/mL of each 
bacterial strain was incubated in 4 μg/mL cefoxitin for 2.5 h, followed by addition of 5 × 108 
pfu/mL 15N-labeled bacteriophage and incubation for an additional 2.5 h at 37 °C. To 
illustrate the capability of PAD to detect S. aureus and determine antibiotic resistance when 
cocultured with another bacterium, S. epidermidis ATCC-35547 and K. pneumoniae 
BAA-1706 were added at equal concentration (1 × 107 pfu/mL) to cultures of cefoxitin-
sensitive S. aureus ATCC-12598 and cefoxitin-resistant S. aureus BAA-1720 prior to phage 
amplification as described above.
Trypsin Digest
Following amplification, samples were prepared for MRM analysis by pelleting out large 
debris from each sample vial via centrifugation, and aliquoting 500 μL of the supernatant 
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into a 100 kDa molecular weight cutoff filter (Amicon Ultra; Millipore, Billerica, MA). 
Each sample was filtered by centrifugation for 10 min at 14 000 rpm and washed twice with 
500 μL of 50 mM ammonium bicarbonate centrifuged through the same filter (10 min at 14 
000 rpm). Subsequently, 10 μL of filter retentate was recovered, combined with 10 μL of 
0.1% Rapigest (Waters, Inc., Bedford, MA), and boiled at 100 °C for 10 min. Upon cooling, 
10 μL of sequence grade trypsin (Promega, Madison, WI) at 0.4 μg/μL was added to the 
sample and enzymatically digest at 52 °C for 3 min. Following digestion, 2 μL of 2 M HCl 
was added to lower the pH for degradation of the Rapigest, and the sample was incubated at 
37 °C for 30 min. Finally, the sample was centrifuged at 14,000 rpm for 10 min to pellet any 
remaining debris, and the supernatant was transferred to LC-MS/MS vials for analysis.
Mass Spectrometry Analysis
Discovery experiments to determine which phage K proteins and corresponding tryptic 
peptides are amenable to mass spectrometric detection were carried out using nanoflow 
liquid chromatography electrospray tandem mass spectrometry combined with database 
searching.23,24 A Waters nano-Aquity HPLC (Waters, Inc., Bedford, MA) was coupled to a 
Thermo Scientific Velos Orbitrap mass spectrometer (San Jose, CA) fitted with a Michrom 
CaptiveSpray source (Bruker-Michrom, Auburn, CA). A BEH130 reverse phase C18, 100 
mm × 100 μm i.d. analytical column was used for reversed phase liquid chromatography 
flowing at 600 nL/min prior to introduction into the mass spectrometer. The aqueous mobile 
phase (A) consisted of 0.1% formic acid with HPLC-grade water (Sigma-Aldrich, St. Louis, 
MO) while the organic phase (B) was composed of HPLC-grade acetonitrile with 0.1% 
formic acid (Sigma-Aldrich, St. Louis, MO). The gradient profile consisted of an initial 
holding at 5% B. After 5 min, the gradient was ramped to 30% B over 90 min, continuing to 
95% B for 15 min, and then returning to 5% B for 20 min for column equilibration. The 
Velos-Orbitrap performed a data-dependent acquisition where the parent ion mass was 
detected in the orbitrap at a resolution of 60,000 and a scan range from m/z 400–1600 amu. 
The top 15 most intense ions were selected for MS/MS in the linear ion trap, where the 
selection window was set at m/z of 2, conventional collision-induced dissociation was 
performed, and dynamic exclusion was enabled with a repeat count of 1 and exclusion 
duration of 120 s.
MS/MS data were extracted from the resulting instrument files using Mascot Distiller 
(Matrix Science, London, UK; version 2.4.2). Database searching was conducted using 
Mascot (Matrix Science, London, UK; version 2.2.0) with the following parameters: peptide 
tolerance of 200 ppm; MS/MS tolerance of 0.8 Da; 2 allowed missed cleavages, variable 
modifications of deamidation (NQ) and oxidation (M); and the enzyme of trypsin. The 
database utilized was the NCBInr (accessed January 14, 2012, www.ncbi.nih.gov) as it has 
the sequences for multiple S. aureus phages, with searches conducted on an in-house, 30-
node Beowulf cluster, with each node consisting of an Intel Xeon, quad-core 3.00 GHz 
processor and 4 GB or RAM. Peptides were validated using Scaflold (version 3.1.2, 
Proteome Software, Inc., Portland, OR),25 with peptide identifications accepted if they could 
be established at a greater than 95.0% probability as specified by the Peptide Prophet 
algorithm.26 Protein identifications were considered valid if they could be established at a 
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greater than 99.0% probability and if they contained at least two peptides with unique amino 
acid sequences.27
Phage K protein sequences identified above were imported into the software program 
Skyline28 to generate and optimize suitable MRM transitions. Candidate peptides for 
detection met the following criteria: length of the peptide was greater than 5 amino acids and 
less than 15 amino acids; the peptide did not contain methionine or cysteine; the peptide did 
not contain any missed cleavages; and arginine or lysine was not followed in sequence from 
the c-terminus by a proline residue. Liquid chromatography was performed using a Waters 
Aquity HPLC (Waters, Inc., Bedford, MA) flowing at 200 μL/min with an aqueous mobile 
phase (A) consisting of 0.1% formic acid with HPLC-grade water and an organic phase (B) 
consisting of HPLC-grade acetonitrile with 0.1% formic acid. A 12 min HPLC method was 
used with the mobile phase beginning at 98%, ramping down to 70% over 5 min, dropping 
to 5% and holding for 3 min, and then returning to 98% for the duration of the run. The 
HPLC flowed into an Applied Biosytems AB SCIEX QTRAP 5500 mass spectrometer with 
an electrospray interface (Framingham, MA) operating in MRM mode. Optimized 
transitions for bacteriophage K were incorporated into an LC/MS/MRM method along with 
calculated transitions for the 15N-labeled bacteriophage. Transitions that emerged following 
prescreening of all possible transitions were then incorporated into a new MRM method 
along with the calculated transitions of the 15N-labeled phage.
RESULTS AND DISCUSSION
Characterization of Bacteriophage K Infections
Bacteriophage K-derived peptides were readily detected by LC-MS/MS analysis coupled 
with database searching, and the inferred proteins, accession numbers, normalized spectral 
counts and molecular weights are shown in Supporting Information Table 1. The most 
abundant protein elicited as determined by spectral counts is the 51 kDa capsid protein of 
phage K. This result is understandable because phage are largely composed of repeating 
protein capsomere units. It is also in agreement with other mass spectrometry studies 
wherein the capsid protein is the most readily detected protein.29 Subsequently, the 
sequences of proteins described in Supporting Information Table 1 were entered into the 
software package Skyline, where transitions were investigated and optimized for MRM 
analysis. Not surprisingly, the transitions yielding the largest peaks as determined by area 
count corresponded to the capsid protein. The transitions utilized throughout this study 
based upon this optimization are the capsid-derived peptides VTATVETK+2Y6 for 
quantitation and HLNEAAVR+2Y6 for confirmation. We used a calibration curve with parent 
phage as the internal standard to estimate wild type bacteriophage concentration.
Utilizing these peptides and transitions, the limit of detection for phage K was determined 
by analyzing serial dilutions of wild type bacteriophage by MRM. Supporting Information 
Figure 1 shows signal/noise ratios of decreasing concentrations of phage K, with S/N 
dropping below 3 between the dilutions of 1.56 × 106 pfu/mL and 7.80 × 105 pfu/mL, 
resulting in an estimated phage K detection limit of ~1 × 106 pfu/mL. Subsequently, an 
estimation of bacterial limit of detection was investigated using serial dilutions of S. aureus 
BAA-1720 and a starting 15N parent bacteriophage concentration of 5 × 108 pfu/mL. 
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Supporting Information Figure 2 shows signal/noise ratios derived from amplified 14N 
progeny phage from decreasing concentrations of S. aureus BAA-1720 after 5 h of 
incubation, with the S/N ratio dropping below 3 at 2.5 × 104 cfu/mL. Thus, for a PAD assay 
concentration, the bacterial limit of detection after 5 h of incubation is ~5 × 104 cfu/mL.
Time to results of the PAD assay using 15N-labeled phage K and S. aureus BAA-1720 was 
determined by measuring 14N progeny signal every 30 min from an infection initiated with 5 
× 108 pfu/mL of 15N parent phage and 1 × 106 cfu/mL of S. aureus. Figure 1 shows a plot of 
estimated 14N progeny phage for each sampling time point as determined by LC-MS/MRM 
analysis. The increase of progeny phage in the sample begins in earnest between 1 and 1.5 h, 
with a plateau in progeny phage concentration occurring at approximately 3.5 h. The data 
presented in Figure 1 are for a single strain of S. aureus BAA-1720, and the time-to-results 
for S. aureus BAA-1720 was experimentally determined to be applicable to the other strains 
of S. aureus utilized throughout this study. However, as PAD assays are developed for the 
broad range of S. aureus strains, time-to-results should be determined for a statistically 
relevant number of S. aureus strains to account for strains that may have a protracted burst 
time or lower efficiencies of plating. For the purposes of this study, an incubation time of 5 h 
for all assays was chosen to ensure that for all conditions (various antibiotics versus no 
antibiotic), sufficient time was allowed to achieve a productive phage amplification event.
S. aureus Detection by PAD
PAD experiments designed to identify multiple strains of S. aureus were based on our 
previously published work10 in which all bacterial strains at a concentration of 1 × 107 
cfu/mL were inoculated with high (5 × 108 pfu/mL) parent 15N phage concentrations. The 
advantages of using a high initial phage concentration are 3-fold: (1) Provided that 
multiplicity of infection (ratio of phage particles to bacteria) is a least 3 and that population 
density of phage and bacteria is high, it is probabilistically likely that all bacteria in the 
sample are infected with a phage particle immediately after inoculation. (2) Because all 
bacteria in the sample are infected immediately after inoculation, the time-to-results for the 
PAD experiment will be minimized. (3) The known, high concentration of isotopically 
labeled bacteriophage can act as an internal standard for accurate bacterial quantitation, as 
all bacteria in a sample have been infected simultaneously thereby effectively eliminating 
secondary amplification events that can skew the accuracy of quantitation.
Figure 2 shows the 14N progeny phage concentration for PAD experiments using a starting 
bacteria concentration of 1 × 107 cfu/mL and a starting 15N parent concentration of 5 × 108 
pfu/mL. For all 4 strains of S. aureus, 14N progeny phage signal was detected after 5 h of 
incubation, signifying a positive phage amplification event and implying the presence of S. 
aureus in each respective sample. Because the starting concentrations of each respective 
bacterium were similar, the signal derived from phage amplification should be similar if this 
assay is to be quantitative as it is in our previous work. The average amplification 
concentration of progeny phage for all 4 strains adjusted to the same starting concentration 
computes to 6.03 ×108 pfu/mL with a relative standard deviation of 19.1%, an impressive 
figure-of-merit considering 4 different strains of bacteria are used.
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Supporting Information Figure 3 shows the calibration curves for strains BAA-1720 and 
ATCC-25923, plotting 14N/15N ratio versus bacterium concentration. For both strains of 
bacteria, a linear relationship is observed across the concentration range that would be 
detectable in a PAD assay, from 5 × 104 to 5 × 107 cfu/mL for each respective bacterium. 
Furthermore, the value of the slope for both calibration curves is similar, indicating that a 
calibration curve for one strain of S. aureus may be used to calculate the concentration of 
another strain of S. aureus.
Determining the concentration of S. aureus in various samples with the calibration curve of a 
single strain of S. aureus hinges on all strains of phage-susceptible bacteria generating a 
similar number of progeny phage following a phage amplification event for a given 
concentration of bacteria. Experimentally, this can be evaluated using the concept of 
efficiency of plating (EOP) which can be defined as the relative number of plaques a phage 
stock can produce on various strains of susceptible bacteria. For example, a phage stock may 
produce an average of 80, 100, 110, and 120 plaques on 4 different strains of susceptible 
bacteria, respectively. By normalizing to the strain producing the lowest number of plaques 
(an arbitrary assignment), the EOP would be 1.0, 1.25, 1.375, and 1.5, respectively for this 
example. Table 2 shows the EOP results of plating the same titer of bacteriophage on the 4 
strains of S. aureus evaluated in this study normalized so that the EOP of BAA-1720 equals 
one. EOP values show relative similarity among the 4 S. aureus strains, indicating that a 
calibration curve from a single strain of S. aureus may be used to quantify all 4 strains in this 
study with a precision and accuracy acceptable in a clinical microbiology laboratory. 
However, EOP values are known to vary considerably,30 a factor that may render 
quantification of a bacterial species from a single strain of that species ineffective. Thus, if 
quantification is desired in a PAD assay covering all strains of a specie, then host range 
analyses testing for phage susceptibility should also ascertain EOP to validate the possibility 
of a quantitative assay from a single-strain calibration curve.
Clindamycin Resistance Determination by PAD
Clindamycin is a lincosamide antibiotic used to treat skin and soft tissue infections and 
pneumonia caused by S. aureus.22 Clindamycin is a protein synthesis inhibitor, binding to 
the 50S ribosomal subunit preventing ribosomal translocation resulting in the stoppage of 
protein production. Phage are reliant upon the protein synthesis machinery of the host 
bacterium to generate phage proteins. Therefore, the effect of clindamycin susceptibility on 
phage replication would be realized in the inability of the host to synthesize progeny phage 
protein. For a PAD experiment using 15N bacteria as the parent phage, the result of 
clindamycin susceptibility would be seen in absence of 14N progeny signal when compared 
with a positive identification for that same strain without the presence of clindamycin.
Figure 3 shows the magnitude of progeny phage amplification for clindamycin susceptibility 
testing on the 4 strains of S. aureus used in this study along with the results of positive 
identification testing with no antibiotic. Inoculations were carried out with starting bacterial 
concentrations of 1 × 107 cfu/mL of S. aureus bacteria and 5 × 108 pfu/mL of 15N 
bacteriophage K, and allowed to proceed for 5 h. Strains BAA-1720 and BAA-1750 show a 
clear, unambiguous PAD signal for the sample containing clindamycin as well as the sample 
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containing no antibiotic. These results are consistent with antibiotic resistance testing using 
traditional methods (Table 1). Further, the strains ATCC-12598 and ATCC-25923 produce 
no detectable signal in the samples containing clindamycin, indicating susceptibility to the 
antibiotic. These results are also consistent with the susceptibility results obtained by 
traditional antibiotic susceptibility testing.
We investigated the effects of increasing clindamycin concentration on progeny phage 
production using the clindamycin resistant strain BAA-1720. Figure 4 shows the results of 
PAD experimentation as clindamycin concentration increased by 2-fold starting with 0.5 
μg/mL and ending with 32.0 μg/mL. While 14N phage amplification is substantial across all 
concentrations of clindamycin, we observed a trend of decreasing output phage 
concentration as antibiotic concentration increased. Output 14N bacteriophage was reduced 
by 50% at 32.0 μg/mL of clindamycin as compared to the no-antibiotic control. This 
reduction in output 14N phage concentration can be explained by clindamycin directly 
hampering the ability of the infected host to produce necessary progeny phage proteins 
despite viability or by a slow-down in overall bacterial doubling time as the bacterial cells 
combat the high concentration of antibiotic. Indeed, Rabinovitch et al. argued that the 
eclipse period, latent period, and “rate of ripening” during the rise period of a bacteriophage 
infection, all independent parameters of bacteriophage development, could be described by 
their dependence solely on the doubling times of the bacterium prior to initiation of an 
infection.31 If doubling times of the bacterium are slowed because an antibiotic is present, 
the magnitude of a bacteriophage amplification event will likely be depressed. This 
depression could become important in cases where the minimum inhibitory concentrations 
of antibiotic are near the defined antibiotic breakthrough point.
Cefoxitin (MRSA) Resistance Determination by PAD
Differing from clindamycin in its mode of action, cefoxitin is a beta-lactam antibiotic that 
exerts its effect by inhibiting cell wall synthesis, thereby blocking the ability of a susceptible 
bacterium to divide. However, until bacteria begin the division process initiating the pathway 
to cell death caused by the action of beta-lactam antibiotics, the protein synthesis pathways 
remain intact and should be able to generate new proteins. Thus, until all bacteria in a 
sample are completely dead because of the effects of cefoxitin, measuring a successful 
phage amplification event in the presence of cefoxitin may be possible, even though the 
bacterial strain may be susceptible to the antibiotic. Indeed, our experimentation 
demonstrates that when a PAD infection is started with initial concentrations (T = 0 h) of 5 × 
108 pfu/mL 15N parent phage and 1 × 107 cfu/mL bacteria in the presence of cefoxitin, a 
sizable production of 14N progeny phage was detected in strains that are clearly sensitive to 
cefoxitin at 4 μg/mL using traditional antibiotic susceptibility testing (Supporting 
Information Figure 4).
To account for the cefoxitin mode-of-action and the presence of still-viable S. aureus cells, 1 
× 107 cfu/mL of each respective S. aureus strain was incubated with no antibiotic (as a 
positive control) and in 4 μg/mL cefoxitin for 2.5 h prior to addition of 5 × 108 pfu/mL 
of 15N parent phage. Following the addition of parent phage, all samples were incubated an 
additional 2.5 h to allow for phage amplification, followed by sample processing and LC-
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MS/MRM analysis as described. Figure 5 displays the results of each respective strain 
incubated in cefoxitin versus a control with no antibiotic. The two MRSA strains 
(BAA-1720 and BAA-1750) used in this study show significant phage amplification in 
cefoxitin versus a control, while the two MSSA strains (ATCC-12598 and ATCC-25923) 
show no significant amplification. The increased magnitude of the phage amplification with 
the cefoxitin resistant strains relative to the no-cefoxitin controls can be explained by the 
significant growth of bacteria that must have occurred in the presence of the antibiotic prior 
to addition of the 15N phage. In the positive controls (no antibiotic, phage added at time= 0 
h), initial phage:bacteria ratios are 50:1, meaning probabilistically every bacterium in the 
sample (1 × 107 cfu/mL) will immediately become infected with a bacteriophage, arresting 
bacterial growth. Thus, initial bacteria concentrations are responsible for the entire 
production of progeny phage observed in the MS signal, and no secondary infections by 
newly generated progeny phage can occur, as all the bacteria have been killed by the phage. 
Conversely, in the samples with cefoxitin, resistant bacteria will experience 2.5 h of growth 
prior to addition of the bacteriophage, resulting in significantly more bacteria responsible for 
generating progeny phage signal relative to the no-cefoxitin control. Further, as the ratio of 
phage:bacteria at time-of-infection is altered due to bacterial growth, the probability of each 
bacterium initially receiving an infectious phage is less. As a result newly released progeny 
phage may find bacteria to infect in a secondary infection, which may also contribute to the 
MS signal
Figure 6 shows the effects of increasing cefoxitin concentration on progeny phage 
production after incubatin-gATCC-1720 in cefoxitin for 2.5 h followed by adding15N parent 
bacteriophage and incubating for an additional 2.5 h. Highest progeny phage production is 
seen in the sample without cefoxitin, resulting in an observable trend. As cefoxitin 
concentration increases, total output phage decreases significantly, until at 128 μg/mL, 
progeny phage production becomes negligible. Clearly, the presence of cefoxitin 
significantly below the MIC attenuates phage production as cellular resources that can 
potentially maximize phage production are diverted to stave off cell death. Phage production 
can also be attenuated, as a cell loses fitness and cellular metabolism, including protein 
synthesis, is compromised. For example, exposure of MRSA strains to subinhibitory 
concentrations of beta-lactam antibiotics induces within minutes the production of penicillin 
binding protein 2A,32 thus plausibly decreasing cellular resources required for progeny 
phage production. Additionally, Qoronfleh and Wilkinson have shown that although a strain 
of S. aureus is resistant to a beta-lactam antibiotic (methicillin), incubation of the strain in 
the presence of subinhibitory methicillin concentrations results in cruder cell walls with 
peptidoglycan containing markedly decreased cross-linking and O-acetylation.33 These 
deficient cell walls lead to increased rates of autolysis and susceptibility to lysing reagents. 
Thus, conceivably, a resistant strain with decreased fitness in the presence of cefoxitin is 
incapable of producing as much progeny phage due to premature lysis caused by diminished 
cell wall integrity.
PAD in Bacterial Mixtures
As demonstrated previously, PAD can be utilized to detect the presence of a bacterial strain 
when cocultured with another bacterial specie.34 To demonstrate this capacity with phage K 
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and S. aureus, we cultured two Gram-positive species of bacteria, the closely related 
Staphylococcus epidermidis and a Klebsiella pneumoniae strain, with a cefoxitin sensitive S. 
aureus (ATCC-12598) and a cefoxitin resistant S. aureus (ATCC-1720), and performed PAD 
experiments as described above. Figure 7 shows the already-demonstrated phage 
amplification of the S. aureus strains when PAD is used for identification in a pure culture, 
while the S. epidermidis and K. pneumoniae show negligible phage amplification. When the 
S. aureus strains are cocultured with the S. epidermidis and K. pneumoniae strains, 
measured phage amplification is similar in magnitude to the PAD experiments using pure 
cultures. Further, when the mixed cultures are subjected to PAD in the presence of 4 μg/mL 
cefoxitin, the cefoxitin sensitive S. aureus shows negligible amplification compared to the no 
cefoxitin control of the mixtures, while the cefoxitin resistant strain shows the significant 
phage amplification as observed above when pure cultures are subjected to the cefoxitin 
testing protocol as described. The ability to detect the presence of S. aureus and determine 
antibiotic sensitivity in bacterial mixtures has profound implications in that an acquired 
sample need not be subcultured for colony isolation prior to analysis. A time-consuming part 
of many bacterial identification work flows is the need to work with isolated colonies of 
bacteria, which can only be obtained by subculture and incubation for a considerable amount 
of time. The ability to detect phage amplification in cocultures of bacteria obviates the need 
for this subculture step. Eliminating this step means that results of bacterial identification 
and antibiotic resistance determination can be obtained during a typical (8 h) work shift, 
including sample prep and incubation time.
Final Assay
Figure 8 shows a schematic of the construct of a complete assay to detect the presence of S. 
aureus in a sample and determine its antibiotic susceptibility to clindamycin and cefoxitin. 
First, a sample is split into 3 aliquots, one containing no antibiotic, one containing 2 μg/mL 
of clindamycin, and one containing 4 μg/mL of cefoxitin. To the aliquots containing no 
antibiotic and clindamycin, 15N-labeled bacteriophage is immediately added and allowed to 
incubate for 5 h. The sample aliquot containing cefoxitin is allowed to incubate for 2.5 h, 
after which 15N-labeled bacteriophage is added, followed by incubation for an additional 2.5 
h. All 3 sample aliquots can be processed for MRM analysis at the 5 h mark, with 
identification and quantitation of bacteria (if desired) occurring in the aliquot with no 
antibiotic, and antibiotic resistance to each respective antibiotic occurring in the other two 
aliquots.
CONSIDERATIONS
The ability of this assay to identify S. aureus and simultaneously determine the phenotypic 
antibiotic resistance patterns for multiple antibiotics in a rapid fashion is significant. Real-
time PCR methods exist for the identification of strains containing the mecA cassette, and 
have been shown to be in agreement with the gold standard of culture.35 However, RT-PCR 
assays can be cost-prohibitive for many laboratories and institutions, and only detect those 
strains containing the mecA cassette thereby ceding the detection of non-mecA resistant S. 
aureus.19 Chromagenic agars for MRSA detection are far more cost-effective than RT-PCR 
assays,36 yet require longer incubation periods for time-to-results. While comparatively 
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mass spectrometry coupled with liquid chromatography as a detection platform for PAD 
assays involves a large initial capital investment, it is not necessarily the detector of choice 
after dissemination of the PAD assay into laboratories. With the advent of MALDI as a 
bacteria detector in many clinical laboratories14,37 the PAD scheme could foreseeably be 
adapted to existing MALDI platforms to ascertain antibiotic resistance, which is currently an 
inherent weakness of MALDI bacterial identification algorithms. Future work on PAD 
techniques will be focused on harnessing the parallel capacity of MALDI to analyze 
numerous phage amplification samples on a platform that is being widely accepted in 
clinical settings.
Similar to issues regarding the use of phage as therapeutics, the use of PAD for identification 
of bacteria and determination of antibiotic resistance hinges on the ability of a phage or 
phage cocktail to infect an acceptable number of strains. Some lytic bacteriophages possess 
a broad host range for a bacterial specie and are currently utilized in laboratory tests for 
identification purposes, such a gamma phage for Bacillus anthracis38,39 and phiA122 for 
Yersinia pestis.40 Many phages have a narrower host range, allowing a defined set of phages 
to be used for phage typing and epidemiological purposes.41–44 Particular to this study, 
bacteriophage K has a broad host range against both coagulase positive and coagulase 
negative Staphylococci, infecting over 70% of S. aureus strains.45 While bacteriophage K 
alone may not be sufficient for a suitable PAD assay, a recent publication using an FDA 
approved phage diagnostic with positive predictive values of 100% for MRSA and MSSA 
shows the viability of a phage based diagnostic for S. aureus.11 Refinement of this assay 
would almost certainly require a cocktail of S. aureus phages.
CONCLUSION
We have shown the ability to identify the presence of S. aureus in a sample and determine 
antibiotic susceptibility to clindamycin and cefoxitin with 5 h of incubation followed by 
mass spectrometric analysis. The unique affinity of bacteriophages for their host combined 
with the sequence-based detection methodology of LC-MS/MRM results in a highly specific 
assay that could plausibly be adapted for use in a clinical lab setting. Furthermore, while two 
antibiotics have been tested for S. aureus susceptibility in this study other antibiotics could 
likely be incorporated into this assay with minimal effort. While the proteinaceous nature of 
bacteriophages makes them ideally suited for detection by mass spectrometry, any method 
capable of detecting changes in protein concentration may be adapted as a detector for phage 
amplification detection, provided an ability to distinguish parent from progeny phage is 
present. This assay could also be developed for other bacteriophage-host bacterial species to 
identify bacteria and determine antibiotic susceptibility. As the specter of antibiotic 
resistance continues to proliferate and with the rise of personalized medicine, the high 
specificity of a bacteriophage assay combined with the ability to rapidly test an infecting 
strain against multiple antibiotics may play a definitive role in achieving positive patient 
outcomes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Time series for phage amplification using 5 × 106 cfu/mL of S. aureus strain BAA-1720 and 
5 × 108 pfu/mL of 15N-labeled bacteriophage. Amplification begins in earnest at 1.5 h, and 
plateaus at 3.5 h.
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Figure 2. 
Phage amplification detection (n = 2) at t = 5 h for 4 strains of S. aureus without the addition 
of antibiotic. Significant amplification of wild-type phage is seen for all 4 strains.
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Figure 3. 
Phage amplification (n = 2) to determine susceptibility of 4 strains of S. aureus to 2 μg/mL 
clindamycin.
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Figure 4. 
Effect on phage amplification with increasing concentrations of clindamycin on the 
clindamycin resistant strain BAA-1720.
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Figure 5. 
Phage amplification detection (n = 2) to determine susceptibility of 4 strains of S. aureus to 
cefoxitin and subsequent MRSA\MSSA designation.
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Figure 6. 
Effects of increasing cefoxitin concentration on phage amplification measured at 5 h using 
S. aureus strain BAA-1720.
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Figure 7. 
Phage amplification detection results of a MSSA (ATCC-12598) and MRSA (BAA-1720) 
strain cultured individually and in the presence of other bacterial species.
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Figure 8. 
Construct of final assay to determine presence of S. aureus in an unknown sample and to 
determine its susceptibility to clindamycin and cefoxitin.
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Table 1
Results of Antibiotic Resistance Testing of Bacterial Strains to Clindamycin and Cefoxitin Using Traditional 
Microbiology Testing Methodology
strain clindamycin resistant cefoxitin resistant
ATCC-12598 no (MIC < 0.5 μg/mL) no (MIC < 0.5 μg/mL)
ATCC-25923 no (MIC < 2 μg/mL) no (MIC < 0.5 μg/mL)
BAA-1720 yes (MIC > 32 μg/mL) yes (MIC > 32 μg/mL)
BAA-1750 yes (MIC > 32 μg/mL) yes (MIC > 32 μg/mL)
ATCC-29213 no (MIC < 0.5 μg/mL) no (MIC < 2 μg/mL)
ATCC-43300 yes (MIC > 32 μg/mL) yes (MIC > 32 μg/mL)
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Table 2
Efficiency of Plating for 4 Strains of S. aureus Normalized to Strain BAA-1720
strain efficiency of plating (EOP)
ATCC-12598 1.4
ATCC-25923 1.6
BAA-1720 1
BAA-1750 1.4
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